May 17, 2020

Who are the most sociable healthcare CIOs on Twitter?

Admin
3 min
Who are the most active healthcare CIOs on Twitter.jpg
Since the first edition of the Huffington Posts most active chief information officers on Twitter, healthcare leadership execs have stepped up to the p...

Since the first edition of the Huffington Post’s most active chief information officers on Twitter, healthcare leadership execs have stepped up to the plate to increase their online presence. Today, healthcare CIOs account for 8 percent of the Post’s 100 most social CIOs on Twitter; ranging from diverse specialties: IT officials, nonprofit gurus and healthcare systems officials, who have joined the online marketplace of healthcare activity.

This increased online presence should not come as a surprise to healthcare professionals, due to the need for virtual marketing and constant social media interaction. It has proven to be just as important as presenting a quality product and service, because if no one is talking about you, then who will buy your product?

MedCity News has provided the following list of the 10 most sociable healthcare CIOs as a resource to healthcare professionals everywhere:

Will Weider (@CandidCIO) is the CIO for Ministry Health and authors the blog Candid CIO

My organization has 1,032 reports with ICD codes that need to be fixed as part of the ICD10 transition. How about yours?

— Will Weider (@CandidCIO) March 21, 2014

John Halamka (@jhalamka) is the CIO for Beth Israel Deaconess Medical Center and authors the blog Life as a Healthcare CIO.

Wearable Computing at BIDMC: Over the past few months, Beth Israel Deaconess has been the pilot site for a new… — John Halamka (@jhalamka) March 12, 2014

Steve Downs (@stephenjdowns) is the CTO and CIO for Robert Wood Johnson Foundation

A conversation w/ Kevin Patrick, @zenchaos @lorimelichar and myself on the promise of #qs data for research: http://t.co/vrn8XK8Nxk — Steve Downs (@stephenjdowns) March 31, 2014

Steve Huffman (@SteveHuffmanCIO) is the CIO for Beacon Health System

Proving again the #ICD10 delay won’t help CIO’s, we are all receiving TONS of requests for projects now that ICD10 is delayed. #docfix — Steve Huffman (@SteveHuffmanCIO) April 2, 2014

Mary Sobiechowski (@msobie) is the CIO of Kantar Health

Finalist new wearable concepts for multiple biometrics #ciomove #cebit works with all apps for data capture COSINUSS pic.twitter.com/etqRQ06y7h — Mary Sobiechowski (@msobie) March 10, 2014

Kevin More (@kmmore) is the CIO for Human Service and Healthcare.org for May Institute, a nonprofit that offers educational, rehabilitative, and behavioral healthcare services to individuals with autism spectrum disorders and other developmental disabilities.

Jump into the SM Flow RT @tomcatalini: “How Being Social Has Made Me A Better CIO” by @PhilKomarny https://t.co/QRgOtSJM65 — Kevin More (@kmmore) March 31, 2014

Glenn Lanteigne (@GlennLanteigne) is the CIO of medical laboratory services business LifeLabs

Did you know that its National Medical Laboratory Week (LabWeek) Apr21-25 to promote awareness of role of medical labs in life @LifeLabs — Glenn Lanteigne (@GlennLanteigne) March 18, 2014

Bill Swavely (@bswavely) is the CIO for BioTelemetry, the company formerly known as CardioNet.

RT @SimplyAfterDark Twitter Tips for Beginners: Everything I Wish I Knew When I Started: http://t.co/NtjsXEQPTi pic.twitter.com/yfyLHn9UKX

— Bill Swavely (@bswavely) April 2, 2014

 

David Chou (@dchou1107) is the CIO for the University of Mississippi Medical Center.

53% of clinicians use tablets daily #mhealth

— David Chou (@dchou1107) April 2, 2014

Jay Ferro (@JayFerro) is the CIO for the American Cancer Society.

Imagination is the highest form of research. ~Albert Einstein #cio #leadership

— Jay Ferro (@jayferro) April 2, 2014



 

Share article

Apr 30, 2021

The challenges to vaccine distribution affecting everyone

covid-19vaccine
vaccinesupply
Supplychain
Blockchain
Jonathan Colehower
5 min
The challenges to vaccine distribution affecting everyone
Jonathan Colehower, CEO at CargoChain, describes the COVID-19 vaccine distribution challenges impacting every country, organisation and individual...

While it is comforting to know that vaccines against COVID-19 are showing remarkable efficacy, the world still faces intractable challenges with vaccine distribution. Specifically, the sheer number of vaccines required and the complexity of global supply chains are sure to present problems we have neither experienced nor even imagined. 

Current projections estimate that we could need 12-15 billion doses of vaccine, but the largest vaccine manufacturers produce less than half this volume in a year. To understand the scale of the problem, imagine stacking one billion pennies – you would have a stack that is 950 miles high. Now, think of that times ten. This is a massive problem that one nation can’t solve alone.  

Production capacity 

Even if we have a vaccine – can we make enough? Based on current projections, Pfizer expects to produce up to 1.3 billion doses this year. Moderna is working to expand its capacity to one billion units this year. Serum Institute of India, the world’s largest vaccine producer, is likely to produce 60% of the 3 billion doses committed by AstraZeneca, Johnson & Johnson and Sanofi. This leaves us about 7 billion doses short. 

Expanding vaccine production for most regions in the world is complicated and time-consuming. Unlike many traditional manufacturing operations that can expand relatively quickly and with limited regulation, pharmaceutical production must meet current good manufacturing practice (CGMP) guidelines. So, not only does it take time to transition from R&D to commercial manufacturing, but it could also take an additional six months to achieve CGMP certification. 

The problem becomes even more complex when considering the co-products required. Glass vials and syringes are just two of the most essential co-products needed to produce a vaccine. Last year, before COVID-19, global demand for glass vials was 12 billion. Even if it is safe to dispense ten doses per vial, there is certain to be significant pressure on world supply of the materials needed to package and distribute a vaccine.

It is imperative drug manufacturers and their raw material suppliers have clear visibility of production plans and raw material availability if there is any hope of optimizing scarce resources and maximising production yield.

Distribution requirements

It is widely known by now that temperature is a critical factor for the COVID-19 vaccine. Even the regions with the most developed logistics infrastructures and resources needed to support a cold-chain network are sure to struggle with distribution.

For the United States alone, State and local health agencies have determined distribution costs will exceed $8.4 billion, including $3 billion for workforce recruitment and training; $1.2 billion for cold-chain, $1 billion vaccination sites and $0.5 billion IT upgrades.  

The complexity of the problem increases further when considering countries such as India that do not have cold-chain logistics networks that meet vaccine requirements. Despite India’s network of 28,000 cold-chain units, none are capable of transporting vaccines below -25°Celsius. While India’s Serum Institute has licensed to manufacture AstraZeneca’s vaccine, which can reportedly be stored in standard refrigerated environments, even a regular vaccine cold chain poses major challenges.

Furthermore, security will undoubtedly become a significant concern that global authorities must address with a coordinated solution. According to the Pharmaceutical Security Institute, theft and counterfeiting of pharmaceutical products rose nearly 70% over the past five years. As with any valuable and scarce product, counterfeits will emerge. Suppliers and producers are actively working on innovative approaches to limit black-market interference. Corning, for example, is equipping vials with black-light verification to curb counterfeiting.

Clearly, this is a global problem that will require an unprecedented level of collaboration and coordination.

Disconnected information systems 

While it is unreasonable to expect every country around the world will suddenly adopt a standard technology that would provide immediate, accurate and available information for everyone, it is not unreasonable to think that we can align on a standard taxonomy that can serve as a Rosetta Stone for collaboration. 

A shared view of the situation (inventory, raw materials, delivery, defects) will provide every nation with the necessary information to make life-saving decisions, such as resource pooling, stock allocations and population coverage.

By allowing one central authority, such as the World Health Organization, to organize and align global leaders to a single collaboration standard, such as GS1, and a standard sharing protocol, such as DSCSA, then every supply chain participant will have the ability to predict, plan and execute in a way that maximises global health.

Political influence and social equality 

As if we don’t have enough stress and churn in today’s geopolitical environment, we must now include the challenge of “vaccine nationalism.” While this might not appear to be a supply chain problem, per se, it is a critical challenge that will hinge on supply chain capabilities.

In response to the critical supply issues the world experienced with SARS-CoV-2, the World Health Organization, Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations (CEPI) formed Covax: a coalition dedicated to equitable distribution of 2 billion doses of approved vaccines to its 172 member countries. Covax is currently facilitating a purchasing pool and has made commitments to buy massive quantities of approved vaccines when they become available.  

However, several political powerhouse countries, such as the United States and Russia, are not participating. Instead, they are striking bilateral deals with drug manufacturers – essentially, competing with the rest of the world to secure a national supply. Allocating scarce resources is never easy, but when availability could mean the difference between life and death, it becomes almost impossible.

Global production, distribution and social equality present dependent yet conflicting realities that will demand global supply chains provide complete transparency and an immutable chain of custody imperative to vaccine distribution. 

The technology is available today – we just need to use it. We have the ability to track every batch, pallet, box, vile and dose along the supply chain. We have the ability to know with absolute certainty that the vaccine is approved, where and when it was manufactured, how it was handled and whether it was compromised at any point in the supply chain. Modern blockchain technologies should be applied so that every nation, institution, regulator, doctor and patient can have confidence in knowing that they are making an impact in eradicating COVID-19.

Share article